Abstract
Leptin has been shown to have a wide repertoire of peripheral effects, some of which are mediated through the central nervous system and others that are induced through a direct action on target tissues. There is now evidence showing that leptin exerts some of its metabolic effects acting directly on peripheral tissues. The role of leptin has expanded from a narrow position in obesity to effects on biological processes, such as diabetes, appetite, thermogenesis, the immune system and reproduction. Here in a first part, we review preclinical evidence for direct effects on specific tissues (neurons, liver and muscle) and metabolic pathways. In a second part we review clinical evidence for leptin effects. In particular we review the effects of recombinant human leptin in lean, obese, diabetic subjects and in patients with congenital leptin deficiency or lipoatrophic diabetes. Additionally, while clinic leptin has not shown dramatic effects in obese / diabetic subjects with measurable serum leptin, in states of leptin deficiency treatment with leptin has been shown to have profound effects on body weight and appetite and insulin resistance.
Keywords: Leptin, thermogenesis, lipoatrophic, neurons, insulin
Current Pharmaceutical Design
Title: Leptin: From Animals to Humans
Volume: 9 Issue: 10
Author(s): Murielle M. Veniant and Carl P. LeBel
Affiliation:
Keywords: Leptin, thermogenesis, lipoatrophic, neurons, insulin
Abstract: Leptin has been shown to have a wide repertoire of peripheral effects, some of which are mediated through the central nervous system and others that are induced through a direct action on target tissues. There is now evidence showing that leptin exerts some of its metabolic effects acting directly on peripheral tissues. The role of leptin has expanded from a narrow position in obesity to effects on biological processes, such as diabetes, appetite, thermogenesis, the immune system and reproduction. Here in a first part, we review preclinical evidence for direct effects on specific tissues (neurons, liver and muscle) and metabolic pathways. In a second part we review clinical evidence for leptin effects. In particular we review the effects of recombinant human leptin in lean, obese, diabetic subjects and in patients with congenital leptin deficiency or lipoatrophic diabetes. Additionally, while clinic leptin has not shown dramatic effects in obese / diabetic subjects with measurable serum leptin, in states of leptin deficiency treatment with leptin has been shown to have profound effects on body weight and appetite and insulin resistance.
Export Options
About this article
Cite this article as:
Veniant M. Murielle and LeBel P. Carl, Leptin: From Animals to Humans, Current Pharmaceutical Design 2003; 9 (10) . https://dx.doi.org/10.2174/1381612033455369
DOI https://dx.doi.org/10.2174/1381612033455369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The New Adipose Tissue and Adipocytokines
Current Diabetes Reviews Fighting Diabetes: Lessons from Xenotransplantation and Nanomedicine
Current Pharmaceutical Design From Adipose Tissue Protein Secretion to Adipopharmacology of Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research Reactive Species, Cellular Repair and Risk Factors in the Onset of Type 2 Diabetes Mellitus: Review and Hypothesis
Current Diabetes Reviews Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Perivascular Adipose Tissue, Inflammation and Vascular Dysfunction in Obesity
Current Vascular Pharmacology Adiponectin as a Target in Obesity-related Inflammatory State
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipotoxicity on the Basis of Metabolic Syndrome and Lipodystrophy in HIV-1-Infected Patients Under Antiretroviral Treatment
Current Pharmaceutical Design Relationship Between Inflammation, Insulin Resistance and Type 2 Diabetes: Cause or Effect?
Current Diabetes Reviews Adipose Tissue as a Target of HIV-1 Antiretroviral Drugs. Potential Consequences on Metabolic Regulations
Current Pharmaceutical Design Treatment Strategy Issues for Chronic HIV-1 Infection in Adults: The Dilemma of Life-long Antiretroviral Treatment
Current Medicinal Chemistry - Anti-Infective Agents Adipose Tissue: Something More than Just Adipocytes
Current Nutrition & Food Science Efficacy and Cardiovascular Safety of Thiazolidinediones
Current Drug Safety Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Leptin- and Leptin Receptor-Deficient Rodent Models: Relevance for Human Type 2 Diabetes
Current Diabetes Reviews